Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Inozyme Pharma Inc
(NQ:
INZY
)
3.550
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 13, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Inozyme Pharma Inc
< Previous
1
2
3
4
Next >
Why Analyst Says Rare Disease-Focused Inozyme Pharma Stock 'Could Be Worth A Look'
September 12, 2024
Stifel initiates coverage on Inozyme Pharma with a Buy rating and a $16 price target, highlighting INZ-701's potential to treat rare diseases like ENPP1 and ABCC6 deficiencies.
Via
Benzinga
This AutoNation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
September 12, 2024
Via
Benzinga
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
August 19, 2024
Via
Benzinga
ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday
August 19, 2024
Via
Benzinga
Inozyme Pharma: Q4 Earnings Insights
March 12, 2024
Via
Benzinga
6 Analysts Have This to Say About Inozyme Pharma
September 27, 2023
Via
Benzinga
INZY Stock Earnings: Inozyme Pharma Misses EPS for Q2 2024
August 06, 2024
INZY stock results show that Inozyme Pharma missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
INZY Stock Earnings: Inozyme Pharma Misses EPS for Q1 2024
May 07, 2024
INZY stock results show that Inozyme Pharma missed analyst estimates for earnings per share the first quarter of 2024.
Via
InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
April 29, 2024
Via
Benzinga
Top 5 Health Care Stocks That May Plunge In March
March 28, 2024
As of March 28, 2024, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Via
Benzinga
Inozyme Pharma Posts Encouraging Data From Rare Calcification Disorders
September 26, 2023
Inozyme Pharma Inc (NASDAQ: INZY) announced interim safety, pharmacokinetic (PK), pharmacodynamic (PD), and exploratory efficacy data from its ongoing Phase 1/2 trials of INZ-701 in adults with
Via
Benzinga
Analyst Expectations for Inozyme Pharma's Future
September 08, 2023
Via
Benzinga
4 Analysts Have This to Say About Inozyme Pharma
August 09, 2023
Via
Benzinga
Analyst Ratings for Inozyme Pharma
April 19, 2023
Via
Benzinga
4 Analysts Have This to Say About Inozyme Pharma
March 23, 2023
Via
Benzinga
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
April 09, 2024
Shares of Tilray Brands, Inc. (NASDAQ: TLRY) fell sharply during Tuesday’s session after the company missed third-quarter estimates and said it no longer expects to generate positive adjusted free
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
September 25, 2023
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
July 27, 2023
Via
Benzinga
Inozyme Outlines Plans For Pediatric Trial For ENPP1 Deficiency Treatment: Targets 2026 Commercial Launch For INZ-701
July 26, 2023
Following meetings with the FDA and the European Medicines Agency's Paediatric Committee, Inozyme Pharma Inc (NASDAQ: INZY) updated its global development strategy for INZ-701, a
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
July 26, 2023
Via
Benzinga
Recap: Inozyme Pharma Q1 Earnings
May 09, 2023
Inozyme Pharma (NASDAQ:INZY) reported its Q1 earnings results on Tuesday, May 9, 2023 at 08:30 AM. Here's what investors need to know about the announcement. Earnings Inozyme Pharma beat estimated...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
April 06, 2023
Via
Benzinga
Why Y-mAbs Therapeutics Shares Are Trading Higher By 50%? Here Are Other Stocks Moving In Friday's Mid-Day Session
March 31, 2023
Gainers Y-mAbs Therapeutics, Inc (NASDAQ: YMAB) climbed 49.9% to $4.93 after the company posted a profit for the fourth quarter.
Via
Benzinga
Around $1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
March 31, 2023
The Dow Jones closed higher by more than 100 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or ...
Via
Benzinga
Why Safe & Green Holdings Shares Are Trading Higher By 30%; Here Are 20 Stocks Moving Premarket
March 30, 2023
Gainers Boxed, Inc. (NYSE: BOXD) gained 43.3% to $0.2303 in pre-market trading after declining 6% on Wednesday. Boxed recently said it is evaluating potentially filing for relief under the U.S....
Via
Benzinga
$1.6M Bet On ATAI Life Sciences? Check Out These 4 Penny Stocks Insiders Are Buying
March 30, 2023
The Dow Jones closed higher by more than 300 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 23, 2023
March 23, 2023
Via
Benzinga
89bio To Rally 265%? Here Are 10 Other Analyst Forecasts For Thursday
March 23, 2023
Baird cut the price target for Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) from $14 to $11. Baird analyst Justin Kleber maintained an Outperform rating. Petco Health and Wellness shares rose...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
February 20, 2023
Via
Benzinga
Why Universal Electronics Shares Are Trading Lower By 30%? Here Are Other Stocks Moving In Friday's Mid-Day Session
February 17, 2023
Gainers Ibio Inc (NYSE: IBIO) shares rose 97% to $1.4787 after the company announced MUC16 as its latest immune-oncology target program.
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.